Full text
3,394 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptides, which are a key factor in its pathogenesis. In this study, we present the design and evaluation of γ-amino-L-proline peptides as metabolically stable, cell-penetrating molecules that can modulate amyloidogenic processing. We screened a library of γ-peptides in primary neuronal cultures to determine their effects on endogenous Aβ1-42 production, cytotoxicity, and β-secretase (BACE1) activity. Comparative analysis of structurally related analogues enabled the identification of molecular features associated with Aβ-lowering activity, establishing a qualitative structure–activity relationship. Peptide 33 (P33) emerged as a lead candidate, selectively reducing BACE1 activity without significantly inhibiting the homologous enzyme, BACE2. In vitro blood-brain barrier (BBB) assays revealed that P33 exhibits favorable transendothelial permeability. Intraperitoneal administration of P33 in APP/PS1 mice decreased Aβ levels, reduced amyloid plaque burden, and improved performance in a behavioral recognition task without inducing cytotoxicity or systemic toxicity. These results define cis-γ-amino-L-proline peptides as a bioorganically distinct and modular scaffold for the development of intracellular modulators of Aβ production.
Highlights
γLJAminoLJLLJproline peptides as metabolically stable modulators of Aβ production.
P33 showed BBB permeability and BACE1 inhibition in primary cortical neurons.
In APP/PS1 mice, P33 lowers amyloid burden and improves cognition.
P33 shows good biocompatibility, supporting its therapeutic potential in AD
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵# R&D Manager at Minoryx Therapeutics, 6041 Gosselies, Walloon Reguin, Belgium.
↵^ Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
↵& Departamento de Química, Universidad del Tolima, 730006299 Ibagué, Colombia
↵° Instituto de Parasitología y Biomedicina López-Neyra (IPB-CSIC), Granada, Spain
- Abbreviations
- ACN
- Acetonitrile
- Amp
- 4-aminoproline
- Braak V–VI
- Braak staging (stages V–VI)
- CGC
- cerebellar granular cells
- CPPs
- Cell-penetrating peptides
- CTX
- neocortex
- DAB
- diaminobenzidine
- DIPEA
- N,N-Diisopropylethylamine
- DIV
- days in vitro
- EDC
- N-Ethyl-N’-(3-dimethylaminopropyl)carbodiimide
- ELISA
- Enzyme-Linked immunosorbent assay
- HBTU
- N-[(1H-benzotriazol-1-yl)-(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide
- HE
- hematoxylin-eosin
- HIP
- hippocampus
- HOBt
- 1-Hydroxybenzotriazole
- ICAM-1
- Intercellular cell adhesion molecule-1
- ICD-10
- International Classification of Diseases 10th Revision
- IL1β
- Interleukin-1β
- ipen
- isopentyl
- MCI
- Mild cognitive deficit
- NINCDS-ADRDA
- National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association
- NFTs
- Neurofibrillary tangles
- NOR
- novel object recognition
- OR
- object recognition test
- PFA
- Paraformaldehyde
- phet
- phenethyl
- RT-qPCR
- Reverse transcription quantitative polymerase chain reaction
- SDS-PAGE
- Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
- SEM
- Standard error of the mean
- SDF-1
- Stromal cell-derived factor-1
- TAT
- Transactivator of transcription
- TNFα
- Tumor necrosis factor α.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.